4/A: Teleflex Inc. Executive Daniel V. Logue Reports Amended Changes in Beneficial Ownership
SEC Form 4/A
Daniel V. Logue, CVP, General Counsel & Secretary of Teleflex Inc., files an amended report detailing changes in beneficial ownership of company stock, including stock option exercises and restricted stock unit awards.
Summary
- On February 26, 2024, Daniel V. Logue exercised stock options to acquire 1,525 shares of Teleflex Inc. common stock at a price of $101.12 per share.
- Also on February 26, 2024, 752 shares were disposed of at $228.5.
- On February 27, 2024, Logue was granted 1,331 restricted stock units (RSUs) under the Teleflex Incorporated 2023 Stock Incentive Plan.
- This Form 4/A amends a previous filing from February 28, 2024, to correct the number of shares underlying Mr. Logue's Restricted Award Unit Award from 1317 to 1331 and the amount of securities beneficially owned following reported transactions.
- Logue directly owns 12,856.888 shares of common stock and indirectly owns 302.795 shares through a 401(k) trustee.
- Logue also acquired 9,332 stock options on February 27, 2024, exercisable in tranches starting February 27, 2025, at an exercise price of $226.04.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. The correction of the RSU grant amount is a positive sign of attention to detail.
Positives
- The granting of restricted stock units and stock options aligns Logue's interests with those of the shareholders, incentivizing him to improve company performance.
- The correction of the RSU grant amount demonstrates attention to detail and transparency in reporting.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the RSUs and stock options indicate a multi-year incentive structure for the reporting person.
Industry Context
Executive stock ownership and option grants are common practices in publicly traded companies to align management's interests with those of shareholders. Form 4 filings are a routine part of regulatory compliance for insiders.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices among publicly traded companies, including Teleflex competitors such as Medtronic, Boston Scientific, and Abbott Laboratories.
- Vesting schedules of three years for RSUs and stock options are also typical in the industry, encouraging long-term commitment from executives.
- The specific amounts and terms of these grants are tailored to the individual executive's role and performance, as well as the company's overall compensation strategy.
Stakeholder Impact
- Shareholders may view the executive's stock ownership and option grants as a positive sign, aligning management's interests with their own.
- Employees may see the grants as part of a competitive compensation package, potentially boosting morale.
Key Dates
| Date | Description |
|---|---|
| 02/26/2015 | Original vesting date for one-third of previously granted stock options. |
| 02/26/2016 | Original vesting date for one-third of previously granted stock options. |
| 02/26/2017 | Original vesting date for one-third of previously granted stock options. |
| 02/26/2024 | Exercise of stock options and disposal of shares. |
| 02/27/2024 | Grant date of restricted stock units and new stock options. |
| 02/27/2025 | First vesting date for one-third of new stock options. |
| 02/27/2026 | Second vesting date for one-third of new stock options. |
| 02/27/2027 | Final vesting date for one-third of new stock options. |
| 02/28/2024 | Date of original filing that this document amends. |
| 06/20/2024 | Date of signature for the amended report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.